Amyloid beta and micrornas in Alzheimer's disease

Nnana Amakiri, Aaron Kubosumi, James Tran, P (Hemachandra) Reddy

    Research output: Contribution to journalReview article

    1 Citation (Scopus)

    Abstract

    Alzheimer's disease (AD) is a progressive mental illness characterized by memory loss and multiple cognitive impairments. In the last several decades, significant progress has been made in understanding basic biology, molecular mechanisms, and development of biomarkers and therapeutic drugs. Multiple cellular changes are implicated in the disease process including amyloid beta and phosphorylation of tau synaptic damage and mitochondrial dysfunction in AD. Among these, amyloid beta is considered a major player in the disease process. Recent advancements in molecular biology revealed that microRNAs (miRNAs) are considered potential biomarkers in AD with a focus on amyloid beta. In this article we discussed several aspects of AD including its prevalence, classifications, risk factors, and amyloid species and their accumulation in subcellular compartments. This article also discusses the discovery and biogenesis of miRNAs and their relevance to AD. Today's research continues to add to the wealth of miRNA data that has been accumulated, however, there still lacks clear-cut understanding of the physiological relevance of miRNAs to AD. MiRNAs appear to regulate translation of gene products in AD and other human diseases. However, the mechanism of how many of these miRNAs regulate both the 5′ and 3′UTR of amyloid precursor protein (APP) processing is still being extrapolated. Hence, we still need more research on miRNAs and APP/amyloid beta formation in the progression and pathogenesis of AD.

    Original languageEnglish (US)
    Article number430
    JournalFrontiers in Neuroscience
    Volume13
    Issue numberMAY
    DOIs
    StatePublished - Jan 1 2019

    Fingerprint

    MicroRNAs
    Amyloid
    Alzheimer Disease
    Amyloid beta-Protein Precursor
    Molecular Biology
    Biomarkers
    Memory Disorders
    Research
    Phosphorylation
    Pharmaceutical Preparations
    Genes

    Keywords

    • Aging
    • Alzheimer's disease
    • Amyloid beta
    • Microrna
    • Mitochondria

    ASJC Scopus subject areas

    • Neuroscience(all)

    Cite this

    Amakiri, N., Kubosumi, A., Tran, J., & Reddy, P. H. (2019). Amyloid beta and micrornas in Alzheimer's disease. Frontiers in Neuroscience, 13(MAY), [430]. https://doi.org/10.3389/fnins.2019.00430

    Amyloid beta and micrornas in Alzheimer's disease. / Amakiri, Nnana; Kubosumi, Aaron; Tran, James; Reddy, P (Hemachandra).

    In: Frontiers in Neuroscience, Vol. 13, No. MAY, 430, 01.01.2019.

    Research output: Contribution to journalReview article

    Amakiri, N, Kubosumi, A, Tran, J & Reddy, PH 2019, 'Amyloid beta and micrornas in Alzheimer's disease', Frontiers in Neuroscience, vol. 13, no. MAY, 430. https://doi.org/10.3389/fnins.2019.00430
    Amakiri, Nnana ; Kubosumi, Aaron ; Tran, James ; Reddy, P (Hemachandra). / Amyloid beta and micrornas in Alzheimer's disease. In: Frontiers in Neuroscience. 2019 ; Vol. 13, No. MAY.
    @article{ecfe812e123b4978bde551e856294216,
    title = "Amyloid beta and micrornas in Alzheimer's disease",
    abstract = "Alzheimer's disease (AD) is a progressive mental illness characterized by memory loss and multiple cognitive impairments. In the last several decades, significant progress has been made in understanding basic biology, molecular mechanisms, and development of biomarkers and therapeutic drugs. Multiple cellular changes are implicated in the disease process including amyloid beta and phosphorylation of tau synaptic damage and mitochondrial dysfunction in AD. Among these, amyloid beta is considered a major player in the disease process. Recent advancements in molecular biology revealed that microRNAs (miRNAs) are considered potential biomarkers in AD with a focus on amyloid beta. In this article we discussed several aspects of AD including its prevalence, classifications, risk factors, and amyloid species and their accumulation in subcellular compartments. This article also discusses the discovery and biogenesis of miRNAs and their relevance to AD. Today's research continues to add to the wealth of miRNA data that has been accumulated, however, there still lacks clear-cut understanding of the physiological relevance of miRNAs to AD. MiRNAs appear to regulate translation of gene products in AD and other human diseases. However, the mechanism of how many of these miRNAs regulate both the 5′ and 3′UTR of amyloid precursor protein (APP) processing is still being extrapolated. Hence, we still need more research on miRNAs and APP/amyloid beta formation in the progression and pathogenesis of AD.",
    keywords = "Aging, Alzheimer's disease, Amyloid beta, Microrna, Mitochondria",
    author = "Nnana Amakiri and Aaron Kubosumi and James Tran and Reddy, {P (Hemachandra)}",
    year = "2019",
    month = "1",
    day = "1",
    doi = "10.3389/fnins.2019.00430",
    language = "English (US)",
    volume = "13",
    journal = "Frontiers in Neuroscience",
    issn = "1662-4548",
    publisher = "Frontiers Research Foundation",
    number = "MAY",

    }

    TY - JOUR

    T1 - Amyloid beta and micrornas in Alzheimer's disease

    AU - Amakiri, Nnana

    AU - Kubosumi, Aaron

    AU - Tran, James

    AU - Reddy, P (Hemachandra)

    PY - 2019/1/1

    Y1 - 2019/1/1

    N2 - Alzheimer's disease (AD) is a progressive mental illness characterized by memory loss and multiple cognitive impairments. In the last several decades, significant progress has been made in understanding basic biology, molecular mechanisms, and development of biomarkers and therapeutic drugs. Multiple cellular changes are implicated in the disease process including amyloid beta and phosphorylation of tau synaptic damage and mitochondrial dysfunction in AD. Among these, amyloid beta is considered a major player in the disease process. Recent advancements in molecular biology revealed that microRNAs (miRNAs) are considered potential biomarkers in AD with a focus on amyloid beta. In this article we discussed several aspects of AD including its prevalence, classifications, risk factors, and amyloid species and their accumulation in subcellular compartments. This article also discusses the discovery and biogenesis of miRNAs and their relevance to AD. Today's research continues to add to the wealth of miRNA data that has been accumulated, however, there still lacks clear-cut understanding of the physiological relevance of miRNAs to AD. MiRNAs appear to regulate translation of gene products in AD and other human diseases. However, the mechanism of how many of these miRNAs regulate both the 5′ and 3′UTR of amyloid precursor protein (APP) processing is still being extrapolated. Hence, we still need more research on miRNAs and APP/amyloid beta formation in the progression and pathogenesis of AD.

    AB - Alzheimer's disease (AD) is a progressive mental illness characterized by memory loss and multiple cognitive impairments. In the last several decades, significant progress has been made in understanding basic biology, molecular mechanisms, and development of biomarkers and therapeutic drugs. Multiple cellular changes are implicated in the disease process including amyloid beta and phosphorylation of tau synaptic damage and mitochondrial dysfunction in AD. Among these, amyloid beta is considered a major player in the disease process. Recent advancements in molecular biology revealed that microRNAs (miRNAs) are considered potential biomarkers in AD with a focus on amyloid beta. In this article we discussed several aspects of AD including its prevalence, classifications, risk factors, and amyloid species and their accumulation in subcellular compartments. This article also discusses the discovery and biogenesis of miRNAs and their relevance to AD. Today's research continues to add to the wealth of miRNA data that has been accumulated, however, there still lacks clear-cut understanding of the physiological relevance of miRNAs to AD. MiRNAs appear to regulate translation of gene products in AD and other human diseases. However, the mechanism of how many of these miRNAs regulate both the 5′ and 3′UTR of amyloid precursor protein (APP) processing is still being extrapolated. Hence, we still need more research on miRNAs and APP/amyloid beta formation in the progression and pathogenesis of AD.

    KW - Aging

    KW - Alzheimer's disease

    KW - Amyloid beta

    KW - Microrna

    KW - Mitochondria

    UR - http://www.scopus.com/inward/record.url?scp=85068554270&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85068554270&partnerID=8YFLogxK

    U2 - 10.3389/fnins.2019.00430

    DO - 10.3389/fnins.2019.00430

    M3 - Review article

    VL - 13

    JO - Frontiers in Neuroscience

    JF - Frontiers in Neuroscience

    SN - 1662-4548

    IS - MAY

    M1 - 430

    ER -